Advanced Search

Cost Analysis of Amlodipine versus Enalapril in Patients with Coronary Artery Disease and Normal Blood Pressure: Findings from the CAMELOT Economic Substudy

Contents:

Author Info

  • Joseph Menzin

    (Boston Health Economics, Inc., Waltham, Massachusetts, USA)

  • Luke Boulanger

    (Boston Health Economics, Inc., Waltham, Massachusetts, USA)

  • Simon Tang

    (Pfizer Inc., New York, New York, USA)

  • Kamlesh Thakker

    (Pfizer Inc., New York, New York, USA)

  • Steven E. Nissen

    (Cleveland Clinic Foundation, Cleveland, Ohio, USA)

Registered author(s):

    Abstract

    Objectives To analyse 2-year hospitalization and cost data collected during a prospective, double-blind, randomized, controlled trial comparing amlodipine, enalapril and placebo in normotensive patients with coronary artery disease (CAD). Methods All patients who were enrolled in the CAMELOT study were included in this economic substudy. Patients with CAD and normal blood pressure were randomized to amlodipine, enalapril or placebo, and followed up for 24 months (between 1999 and 2004). Data on hospitalizations and medication use were obtained from the clinical trial. Costs were assigned from secondary sources. Total costs ($US, year 2004 values) were estimated as the sum of costs associated with cardiovascular hospitalizations, study medications and concomitant cardiovascular medications. Costs and resource use were analysed by treatment arm overall and for selected patient subgroups. Cost differences were evaluated using nonparametric bootstrap techniques. Results Of 1991 patients enrolled, 663 were treated with amlodipine, 673 were treated with enalapril and 655 were treated with placebo. Significantly fewer patients were hospitalized for cardiovascular reasons in the amlodipine group (16.4%) than in the placebo group (22.7%; p <0.01), but not compared with the enalapril group (20.1%; p-0.09). The amlodipine group also had numerically fewer days in hospital per patient (1.1) than the enalapril (1.3) and placebo (1.5) groups. Mean 2-year per-patient costs in the amlodipine group were estimated to be $US609 and $US717 lower than for the placebo and enalapril groups, respectively. Conclusions These results suggest that use of amlodipine may reduce costs of care among CAD patients with normal blood pressure.

    Download Info

    If you experience problems downloading a file, check if you have the proper application to view it first. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.
    File URL: http://healtheconomics.adisonline.com/pt/re/ahe/pdfhandler.00148365-200806020-00001.pdf
    Download Restriction: Pay per view
    File URL: http://healtheconomics.adisonline.com/pt/re/ahe/fulltext.00148365-200806020-00001.htm
    Download Restriction: Pay per view

    As the access to this document is restricted, you may want to look for a different version under "Related research" (further below) or search for a different version of it.

    Bibliographic Info

    Article provided by Springer Healthcare | Adis in its journal Applied Health Economics & Health Policy.

    Volume (Year): 6 (2008)
    Issue (Month): 2-3 ()
    Pages: 157-162
    Download reference. The following formats are available: HTML (with abstract), plain text (with abstract), BibTeX, RIS (EndNote, RefMan, ProCite), ReDIF
    Handle: RePEc:wkh:aheahp:v:6:y:2008:i:2-3:p:157-162

    Contact details of provider:
    Web page: http://healtheconomics.adisonline.com/

    For corrections or technical questions regarding this item, or to correct its listing, contact: (Dave Dustin).

    Related research

    Keywords:

    Find related papers by JEL classification:

    References

    No references listed on IDEAS
    You can help add them by filling out this form.

    Citations

    Lists

    This item is not listed on Wikipedia, on a reading list or among the top items on IDEAS.

    Statistics

    Access and download statistics

    Corrections

    When requesting a correction, please mention this item's handle: RePEc:wkh:aheahp:v:6:y:2008:i:2-3:p:157-162

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Dave Dustin).

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If references are entirely missing, you can add them using this form.

    If the full references list an item that is present in RePEc, but the system did not link to it, you can help with this form.

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your profile, as there may be some citations waiting for confirmation.

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.